Mednet Logo
SpecialtiesAllergy & Immunology
Allergy & Immunology

Allergy & Immunology

Expert discussions on allergic conditions, immunodeficiencies, drug hypersensitivity, and immunotherapy approaches.

Recent Discussions

How are you addressing accurate dissemination of information to patients with the increase in inaccurate information in the digital era?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Washington University School of Medicine

There are some patients who have already “fallen down the rabbit hole” and are unlikely to be convinced of anything other than the inaccurate information. With these patients, I try to use diplomatic speech such as “we don’t have good evidence/data for this,” “that would be pretty atypical,” or “it ...

How do you address the discrepancy between traditional allergy skin testing and the Rinkel skin test results?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Allergy And Asthma Consultants Of Rockland And Bergen

No one asks about the Rinkel skin test.

Do you utilize AIT for atopic dermatitis if there is no AR present?

4 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Baylor College of Medicine

Allergen Immunotherapy (AIT) was included as an adjunctive treatment option for patients with moderate to severe atopic dermatitis (AD) in the updated 2023 Guidelines for Atopic Dermatitis. The recommendation was made based on results from a systematic review and meta-analysis of 23 randomized contr...

What do you consider an appropriate observation period following resolution of anaphylaxis signs and symptoms given the risk of biphasic reactions?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Allervie Health Huntsville

4 hours.

For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?

1 Answers

Mednet Member
Mednet Member
Rheumatology · The Feinberg School of Medicine, Northwestern University

When deciding whether it is safe to re-challenge with rituximab after an infusion reaction, the most important consideration is the type of reaction that the patient experienced. This will help to risk stratify and determine whether same day or future infusions of RTX should be used. Importantly, th...

What were your top takeaways from ACAAI 2025?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · University of Chicago

I really liked the session titled "Practical approaches to mast cell concerns".My colleagues and I were discussing this recently seems like we are seeing more people concerned about mast cell activation syndrome, but their history and symptoms do not meet the criteria. What to do? Some interesting a...

What type of DES should you opt for if a patient has or is concerned about possible nickel allergy?

2 Answers

Mednet Member
Mednet Member
Cardiology · Unitypoint

For a coronary stent, I would lean toward a Medtronic DES. There are published recommendations for nitinol with a durable polymer. That said, I cannot remember more than one case in 25 years where I thought that a metal allergy may have played a role in a patient receiving a stent and that was prior...

Is addition of SLIT likely to provide additional benefit for isolated dust mite allergy that is not completely treated with SCIT?

2
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Ent And Allergy Associates Lake Success

I offer both and have patient decide.

How are you selecting between oral therapies and parenteral treatments for managing hereditary angioedema attacks?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · PennState Health

I use shared decision making by explaining the route of therapy, how often the medicine is given, the efficacy, and the side effects of the medications and allow the patient to decide what drug they would prefer.

In a patient with HAE and on prophylaxis for HIV, who has failed Tazhyro and Orladeyo and breakthrough on Cinryze, what do you recommend for prophylaxis?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · PennState Health

First of all, the failure to respond to lanadelumab and berotralstat makes me think that the patient may not have hereditary Angioedema. If they did, I would suspect it would be a patient with the diagnosis of hereditary Angioedema with normal C1-inhibitor. The first thing I would ask is if the pati...